Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Tanta University

Status and phase: Enrolling; Phase 3

Conditions: IBS - Irritable Bowel Syndrome

Treatments: Drug: ethosuximide; Drug: pentoxyifylline; Drug: Mebeverine

Study type: Interventional

Funder types: Other

Identifiers

NCT04217733

Sherief Protocol

Details and patient eligibility

About

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Full description

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome: Does this add to current treatment?

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age ≥ 18 years,

  • Man and Women, Negative pregnancy test and effective contraception,
  • IBS defined by the Rome criteria IV
  • During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
  • IBS Treatment stable for 1 month

Exclusion criteria

• • Breastfeeding

  • Diabetic patients
  • Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)
  • Addiction to alcohol and / or drugs,
  • Antiepileptic drugs taken (epilepsy or chronic pain)
  • Chronic pain of greater intensity than that related to IBS,
  • Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.
  • History or current severe depression (hospitalization, long-term antidepressant treatment)
  • Psychotic disorders,

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 3 patient groups

Mebeverine

Active Comparator group

Description:

Mebeverine 3 times daily for 3 months

Treatment:

Drug: Mebeverine

Ethosuximide

Experimental group

Description:

Ethosuxemide 3 times daily for 3 months

Treatment:

Drug: ethosuximide

Pentoxyifylline

Experimental group

Description:

pentoxyifylline 2 times daily for 3 months

Treatment:

Drug: pentoxyifylline